

Date: June 2, 2008

Re: Current Master Clinical Trial Agreement

---

Name of the company, sponsor (Agreement Period)

- **Astellas** Pharma US, Inc. (05/09/07 – 06/30/09)
- **Bayer** Pharmaceuticals Corporation (05/14/08 – 05/14/13)
- **Biogen**, Inc. (07/06/99 – N/A)
- **Bristol-Myers Squibb Medical Imaging** (06/21/04 – until the completion of the last Study to be performed)
- **DuPont** Pharmaceuticals Company (05/08/01 – until terminated pursuant to Section 1B)
- **Cook** Biotech Incorporated (10/30/06 -10/30/13)
- **Genzyme** Corporation (01/01/03 – until it is mutually terminated)
- **GlaxoSmithKline** /SmithKline Beecham Corporation (10/07/03 – until terminated as provided in Section 4)
- **Gilead** Sciences, Inc. (05/17/07 – 5/17/14)
- **ILEX** Products, Inc. (07/16/04 – N/A)
- **Novartis** (12/01/05 – 12/01/10)
- **Pfizer** Global Pharmaceuticals
  1. Master Clinical Study Agreement (05/01/06 – 4/30/11)
  2. Master Investigator-Initiated Research Agreement (Only For Observational and Post-Marketing Drug Studies, doesn't cover basic science agreement) (04/28/06 – 04/28/11)
- **Roche** Pharmaceuticals – Palo Alto, a division of Syntex /Hoffmann-La Roche Inc.(03/07/97 – N/A)

- **Schering-Plough** Research Institute (09/18/03 – 09/18/08)
- **Sanofi-aventis** U.S. Inc. (02/05/07 – 02/05/12)
- **Tanox, Inc.** (07/16/02 – until terminated pursuant to Section 1b)